文献速递前列腺癌

阿帕他胺与恩扎卢胺在非转移性去势抵抗性前列腺癌中的间接比较

Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide.
PubMed 文献 · Eur Urol Oncol · 2018-05-15

该研究采用网络荟萃分析中的Bucher技术,以安慰剂为共同对照,间接比较阿帕他胺与恩扎卢胺在非转移性去势抵抗性前列腺癌(nmCRPC)患者中的相对疗效与毒性。主要终点为无转移生存期(MFS),次要终点包括至前列腺特异性抗原进展时间、总生存期和不良事件。结果显示恩扎卢胺与阿帕他胺在MFS上无显著差异(风险比1.04,95%置信区间0.78-1.37),所有次要终点亦无差异。作者认为间接比较不能替代直接比较数据,但提示两药在延迟转移方面效果相似。

要点

  • 恩扎卢胺对比阿帕他胺的MFS风险比为1.04(95%CI 0.78-1.37),无显著差异。
  • 至PSA进展时间、总生存期及不良事件等次要终点均无差异。
  • 间接比较不能替代直接比较数据,但提示两药疗效与副作用谱可能相似。

核心结论

  • 恩扎卢胺与阿帕他胺在nmCRPC患者中延迟转移的疗效相似,MFS风险比1.04(95%CI 0.78-1.37),无显著差异。
  • 所有次要终点(至PSA进展时间、总生存期、不良事件)均无差异。
  • 间接比较不能替代直接比较数据,但该分析提示两药疗效与副作用谱可能相似。

研究设计与样本

  • 采用网络荟萃分析中的Bucher技术进行间接治疗比较,以安慰剂为共同对照。
  • 比较阿帕他胺与恩扎卢胺在非转移性去势抵抗性前列腺癌患者中的相对疗效与毒性。
  • 主要终点为无转移生存期(MFS),次要终点为至前列腺特异性抗原进展时间、总生存期和不良事件。

主要发现

  • 恩扎卢胺对比阿帕他胺的MFS风险比为1.04(95%CI 0.78-1.37),无显著差异证据。
  • 所有次要终点均无差异。

关键数值与推荐

  • MFS风险比1.04(95%CI 0.78-1.37),恩扎卢胺对比阿帕他胺。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 间接比较不能替代直接比较数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) have historically had few treatment options. Recently, randomized controlled trials have examined the benefit of apalutamide and enzalutamide in these patients. We sought to perform an indirect treatment comparison using a network meta-analysis approach to compare the relative efficacy and toxicity of these two agents. The primary outcome of this analysis was metastasis-free survival (MFS) while secondary outcomes were time to prostate-specific antigen progression, overall survival, and adverse events. The Bucher technique for indirect comparison was used to compare apalutamide and enzalutamide using the common placebo comparator. We found no evidence of a significant difference in MFS (hazard ratio 1.04, 95% confidence interval 0.78-1.37) between enzalutamide and apalutamide. Similarly, there were no differences for any of the secondary outcomes. While indirect comparisons cannot supplant direct comparative data, this analysis suggests that apalutamide and enzalutamide are similarly effective in delaying metastases for patients with nmCRPC. PATIENT SUMMARY: Historically, there have been few treatment options for prostate cancer patients receiving androgen deprivation therapy who have rising prostate-specific antigen levels without obvious recurrence of cancer. Recent randomized controlled trials demonstrated that treatment with enzalutamide and apalutamide delayed the development of metastatic cancer. This study demonstrates through an indirect comparison that both medications are likely to have similar efficacy and side-effect profiles.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Wallis CJD, Chandrasekar T, Goldberg H, et al. Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide. Eur Urol Oncol. 2018. PMID: 31102627. doi:10.1016/j.euo.2018.04.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。